Penumbra Inc
NYSE:PEN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
163.64
273.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Penumbra Inc
Penumbra Inc
Interest Income Expense
Penumbra Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Penumbra Inc
NYSE:PEN
|
Interest Income Expense
$11.9m
|
CAGR 3-Years
109%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Interest Income Expense
-$364m
|
CAGR 3-Years
1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-15%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Interest Income Expense
-$564m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
2%
|
CAGR 10-Years
-11%
|
|
|
Stryker Corp
NYSE:SYK
|
Interest Income Expense
$127m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Abbott Laboratories
NYSE:ABT
|
Interest Income Expense
-$247m
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-12%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Interest Income Expense
$315.7m
|
CAGR 3-Years
54%
|
CAGR 5-Years
21%
|
CAGR 10-Years
39%
|
|
Penumbra Inc
Glance View
Penumbra Inc. is revolutionizing the landscape of medical technology with its innovative solutions tailored to treat some of the most challenging conditions in neuro and peripheral vascular health. Founded in 2004, the company has swiftly positioned itself as a leader in developing devices that empower physicians to provide advanced, minimally invasive treatment options. Penumbra's flagship products, including the Penumbra System for thrombectomy and its suite of neurovascular devices, showcase its commitment to enhancing patient outcomes and streamlining procedures. With a strong focus on research and development, the company aims to address unmet medical needs, thus facilitating its growth trajectory in a market with substantial demand. As an investment opportunity, Penumbra Inc. stands out not only for its robust pipeline of innovative technologies but also for its impressive financial performance. The company has demonstrated strong revenue growth driven by increasing market adoption of its products and strategic expansions into new therapeutic areas. With healthcare's ongoing shift toward minimally invasive treatments, Penumbra is ideally positioned to capitalize on this trend, supported by a team of experienced professionals and a culture of innovation. For investors, Penumbra offers a compelling blend of growth prospects and the potential for long-term returns as it continues to redefine standards of care in the medical device industry.
See Also
What is Penumbra Inc's Interest Income Expense?
Interest Income Expense
11.9m
USD
Based on the financial report for Sep 30, 2024, Penumbra Inc's Interest Income Expense amounts to 11.9m USD.
What is Penumbra Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
32%
Over the last year, the Interest Income Expense growth was 325%. The average annual Interest Income Expense growth rates for Penumbra Inc have been 109% over the past three years , 32% over the past five years .
You don't have any saved screeners yet
